5LUB

Crystal structure of human legumain (AEP) in complex with compound 11

5LUB の概要

• エントリーDOI: 10.2210/pdb5lub/pdb
• 分子名称: Legumain, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (5 entities in total)
• 機能のキーワード: cysteine protease, allosteric inhibitor, asparaginyl endopeptidase, alzheimer's disease, hydrolase
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 61825.01

構造登録者

Dall, E.,Ye, K.,Brandstetter, H. (登録日: 2016-09-08, 公開日: 2017-03-29, 最終更新日: 2024-11-06)

主引用文献

Zhang, Z.,Obianyo, O.,Dall, E.,Du, Y.,Fu, H.,Liu, X.,Kang, S.S.,Song, M.,Yu, S.P.,Cabrele, C.,Schubert, M.,Li, X.,Wang, J.Z.,Brandstetter, H.,Ye, K.
Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer's disease.
Nat Commun, 8:14740-14740, 2017

PubMed Abstract: δ-secretase, also known as asparagine endopeptidase (AEP) or legumain, is a lysosomal cysteine protease that cleaves both amyloid precursor protein (APP) and tau, mediating the amyloid-β and tau pathology in Alzheimer's disease (AD). Here we report the therapeutic effect of an orally bioactive and brain permeable δ-secretase inhibitor in mouse models of AD. We performed a high-throughput screen and identified a non-toxic and selective δ-secretase inhibitor, termed compound 11, that specifically blocks δ-secretase but not other related cysteine proteases. Co-crystal structure analysis revealed a dual active site-directed and allosteric inhibition mode of this compound class. Chronic treatment of tau P301S and 5XFAD transgenic mice with this inhibitor reduces tau and APP cleavage, ameliorates synapse loss and augments long-term potentiation, resulting in protection of memory. Therefore, these findings demonstrate that this δ-secretase inhibitor may be an effective clinical therapeutic agent towards AD.

PubMed: 28345579
DOI: 10.1038/ncomms14740

実験手法

X-RAY DIFFRACTION (2.1 Å)